TrialJournal for immunotherapy of cancer2025

Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer.

Yoon-Koo Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.